Trial Profile
A Phase I/II Evaluation of Olaparib in Combination With Durvalumab (Medi4736) and Tremelimumab in the Treatment of Recurrent Platinum Sensitive or Resistant or Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Patients Who Carry a BRCA1 or BRCA2 Mutation
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 22 Feb 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Olaparib (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 15 Feb 2024 Planned End Date changed from 1 Feb 2024 to 15 Oct 2024.
- 30 Jan 2024 Planned End Date changed from 15 Dec 2023 to 1 Feb 2024.
- 13 Oct 2023 Planned End Date changed from 15 Sep 2023 to 15 Dec 2023.